Morgan Creek - Exos SPAC ... (SPXZ)
AMEX: SPXZ
· Real-Time Price · USD
11.01
0.01 (0.12%)
At close: Jun 12, 2025, 3:41 PM
0.12% (1D)
Bid | - |
Market Cap | 6.25M |
AUM | 6.26M |
NAV | 11.02 |
EPS (ttm) | n/a |
PE Ratio (ttm) | n/a |
Shares Out | 567.55K |
Inception Date | Jan 25, 2021 |
Ask | - |
Volume | 1.89K |
Open | 10.98 |
Previous Close | 11.00 |
Day's Range | 10.98 - 11.01 |
52-Week Range | 10.98 - 11.01 |
Holdings | 102 |
Expense Ratio | 1.00% |
About SPXZ
The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in U.S.-listed special purpose acquisition companies ("SPACs") and in companies that have merged with or been acquired by a SPAC. A SPAC is a "blank check" company with no commercial operations that is designed to raise capital via an initial public offering ("IPO") for the purpose of engaging in a merger, acquisition, reorganization, or similar business combination (a "Combination") with one or more operating companies. The fund is non-diversified.
Asset Class Equity
Ticker Symbol SPXZ
Inception Date Jan 25, 2021
Provider Other
Website Fund Home Page
Exchange AMEX
Top Sectors
Sector | Weight % |
---|---|
Financial Services | 50.82% |
Technology | 14.42% |
Industrials | 12.06% |
Consumer Cyclical | 7.54% |
Healthcare | 6.55% |
Top 10 Holdings 15.68% of assets
Name | Symbol | Weight |
---|---|---|
Purecycle Technologi... | PCT | 1.77% |
Chargepoint Holdings... | CHPT | 1.65% |
Embark Technology, I... | EMBK | 1.59% |
Hillman Solutions Co... | HLMN | 1.59% |
Danimer Scientific, ... | DNMR | 1.58% |
Mp Materials Corp. | MP | 1.56% |
Cash & Other | Cash&Other | 1.50% |
Humacyte, Inc. | HUMA | 1.50% |
Joby Aviation, Inc. | JOBY | 1.48% |
Cano Health, Inc. | CANO | 1.46% |
Dividends Dividend Yield 0.49%
Ex-Dividend | Amount | Payment Date |
---|---|---|
Dec 28, 2021 | $0.0780 | Dec 30, 2021 |

3 years ago · seekingalpha.com
BFAC And The SPAC ProblemBFAC And The SPAC Problem

3 years ago · seekingalpha.com
Spotlight On SPACs: More Risk Than Opportunity?Spotlight On SPACs: More Risk Than Opportunity?